“Olaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation.”
“Nine (3%) patients in the overall study population, who were randomised on the basis of a locally identified BRCA1/2 mutation, did not go on to have their BRCA1/2 mutation confirmed as deleterious, or suspected deleterious, by the Myriad Genetics BRCA test as part of the trial. An analysis of progression-free survival that excluded these nine patients showed an HR in favour of olaparib that was highly consistent with the investigator-assessed primary endpoint. These data indicate that the progression-free survival improvement reported for patients receiving olaparib in our trial was not changed by the inclusion of patients who did not have Myriad confirmation of their BRCA1/2 mutation.”
Pujade-Lauraine E, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet, 2017.
Learn More View Article